ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1080

Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study

Antoine Minier1, Gilles Boire1, Sophie ROUX1, Nathalie Carrier2 and Hugues Allard-Chamard1, 1Université de Sherbrooke, Sherbrooke, QC, Canada, 2CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada

Meeting: ACR Convergence 2023

Keywords: Anti-TNF Drugs, Drug toxicity, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) are used to treat a variety of inflammatory conditions ranging from rheumatoid arthritis to sarcoidosis. Paradoxical side-effects (PSE) of TNFi include the development of conditions normally treated by the therapeutic agent, such as psoriasis and uveitis. Most prevalent among these adverse effects is paradoxical psoriasis, described as having a prevalence of 4.6%1 in patients with inflammatory bowel disease (IBD). Our objective was to validate the prevalence and incidence of PSE in TNFi treatment of rheumatic diseases (RD) patients and to identify risk factors.

Methods: Using our institution’s database on biologic agents in RD, patients that used TNFi were identified. Chart review was performed to identify PSE, which were either documented by the treating clinician or defined as the onset of a condition treatable by the biologic agent (psoriasis, uveitis, hidradenitis suppurativa (HS) or IBD). To identify risk factors, demographic information, diagnosis, and duration of treatment were recorded.

Results: From 2003 to 2023, 1184 patients used at least one TNFi. Median age at diagnosis was 46.1 years old, and females made up 55% of the population. 39% of patients had rheumatoid arthritis while 61% of patients had spondyloarthritides (37% psoriatic arthritis; 63% with other spondylarthropathies). 35 PSE were identified, including 23 cases of psoriasis, 4 cases of Crohn’s disease, 3 psoriasis exacerbations , 2 palmoplantar pustulosis, 2 uveitis and 1 HS. The prevalence of PSE across our population was 3.0% (95% CI 2.1 – 4.1). Patients in the SpA group were three times more likely to experience a PSE when compared to RA with a prevalence of 5.1% vs 1.7% (OR (95% CI) = 3.06 (1.36 – 6.92), p< 0.01). A difference was also observed when comparing prevalence in SpA versus PsA (OR=3.56 (1.22 – 10.41), p=0.02) , while patients younger than 50 years old were more likely to experience PSE (OR=2.34 (1.16 – 2.75), p=0.02).Smoking was a risk factor (OR=2.19 (1.02 – 4.83), p=0.05). Etanercept was less likely to be used in the SpA group compared to the RA group (OR=0.27 (0.20 – 0.36), p< 0.01). Incidence of PSE per 1000 patient-years was 7.9 (95% CI : 4.4 – 13.1) for adalimumab, 2.9 (1.2 – 5.7) for etanercept, 6.4 (1.8 – 16.5) for infliximab, 6.5 (2.1 – 15.3) for golimumab and 9.2 (1.9 – 26.8) for certolizumab. The incidence rate ratio between adalimumab and etanercept was statistically significant (IRR=2.76 (1.10 – 7.52), p=0.02).

Conclusion: Our results identify an overall prevalence of 3.0% for PSE, with a prevalence of 5.1% in SpA, closely matching the prevalence previously reported in IBD. Our results suggest a higher prevalence of PSE in SpA compared to RA. Predisposition to psoriasis in SpA or cutaneous psoriasis appearing after diagnosis of PsA are likely explanations for these results. The use of the decoy receptor, etanercept, compared to monoclonal antibodies was an important protective factor, explained in part by its lesser use in the SpA group. 1. Xie W, Xiao S, Huang H, Zhang Z. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis. Front Immunol. 2022;13:847160.

Supporting image 1

Supporting image 2


Disclosures: A. Minier: None; G. Boire: Eli Lilly, 1, Janssen, 6, Organon, 1, Orimed Pharma, 1, 6, Otsuka, 1, Pfizer, 1, 5, Sandoz, 1, Teva, 1, Viatris, 1, 6; S. ROUX: Amgen, 6, Kyowa kirin, 12, Journal Club, Novartis, 6; N. Carrier: None; H. Allard-Chamard: AbbVie/Abbott, 1, 5, 6, Amgen, 1, 6, AstraZeneca, 1, 6, Bristol-Myers Squibb(BMS), 1, 5, 6, Celltrion, 1, 6, Eli Lilly, 1, 5, 6, Fresenius Kabi, 5, 6, GlaxoSmithKlein(GSK), 1, Hoffmann-La Roche, 1, 6, Janssen, 1, 6, Mantra Pharma, 6, Novartis, 1, 5, 6, Pfizer, 1, 5, 6, Sanofi, 5, Sobi, 6, Viela Bio, 5, Xencor, 5.

To cite this abstract in AMA style:

Minier A, Boire G, ROUX S, Carrier N, Allard-Chamard H. Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-incidence-of-paradoxical-side-effects-of-tnf-%ce%b1-inhibitors-a-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-incidence-of-paradoxical-side-effects-of-tnf-%ce%b1-inhibitors-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology